Acute Leukemias | Eunice Wang, MD

published 1 month ago by Dr Neil Love

Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice: Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00) Molecular profiling in the diagnosis and treatment of AML (01:54) Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14) CPX-351 for secondary AML (07:16) Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45) Clinical experience with and tolerability of gilteritinib (16:12) Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54) Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17) Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50) Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01) Activity and safety of immune checkpoint inhibitors in patients with AML (32:58) Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06) Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32) Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22) Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15) Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56) Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23) Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33) Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17) Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34) Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19) Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44) Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51) CME information and select publications

more episodes from Research To Practice | Oncology Videos